Actos Settlement Payouts Total Millions for Actos Bladder Cancer Victims. New York Attorney General Eric Schneiderman announced that the drug manufacturer, Mylan Pharmaceuticals LLC has agreed to pay $90 million in settlement money back to bladder cancer patients who were part of a lawsuit against them.
The “pioglitazone banned” is a settlement that has been made to Actos bladder cancer victims. The total amount of the settlement is millions of dollars.
Settlement of Actos
Takeda, the manufacturer of Actos, agreed to a $2.4 billion deal in 2015 to address hundreds of Actos bladder cancer cases.
At the time, there were about 9,000 Actos bladder cancer litigation pending. The complaints claimed that the manufacturer concealed the diabetic medication’s bladder cancer risk. Based on its own research, Takeda knew or should have known about the Actos bladder cancer risk, according to the Actos claims.
Takeda knew about the bladder cancer risk from both animal research before Actos was launched and human clinical trials in the early 2000s, according to the Actos bladder cancer cases.
Family members of loved ones who purportedly died as a consequence of Actos bladder cancer have also filed Actos lawsuits.
Takeda maintained that Actos was not to blame for the development of bladder cancer in some Actos patients even after agreeing to the $2.4 billion Actos settlement in 2015.
In a 2014 trial, a jury found Takeda and Eli Lilly, who assisted in the marketing of the medication, liable for $9 billion in punitive penalties for concealing the risk of cancer associated with Actos. A court lowered the sum to $36.8 million.
Class Action Lawsuit Against Actos for Bladder Cancer
In May 2018, an Actos bladder cancer class action lawsuit was filed against Takeda and Eli Lilly. Patients paid for a “ineffective and hazardous” diabetic medication, according to the Actos class action lawsuit.
According to the Actos class action complaint, the drug manufacturers withheld information regarding the connection between Actos and bladder cancer because they “understood that if the medical community knew that Actos might cause bladder cancer, it would not have been the blockbuster medication they wanted Actos to be.”
After the FDA authorized Actos in 1999 to help diabetic patients manage their blood sugar, it quickly became a top-selling medication. Actos sales totaled more than $2.6 billion in 2010.
Patients claim that although the drugmakers deceived the public and medical community into thinking the medication was safe, “the consequences were devastating—many thousands of patients developed bladder cancer and the Defendants earned billions,” according to the lawsuit.
Investigation into the Actos Lawsuit
You may be eligible to file an Actos case and get an Actos compensation if you or a loved one took Actos and got bladder cancer. Fill out the FREE form on this page to become a part of the Actos lawsuit investigation.
Actos Settlement Payouts Total Millions for Actos Bladder Cancer Victims. The “pioglitazone black box” is a medication that was used to treat type 2 diabetes. It was taken off the market in 2012 after it was found to cause bladder cancer.
Frequently Asked Questions
Does Actos cause bladder cancer?
A: Actos is a brand name for the drug metformin. While it does not cause cancer, there are some links to bladder and kidney cancers that have been found in studies on animals with high doses of this medication.
Does Actos cause prostate cancer?
A: No, Actos does not cause prostate cancer.
What pharmaceutical company makes Actos?
A: Takeda Pharmaceuticals, a Japanese company based in Osaka.
- actos and trulicity
- actos manufacturer
- actos vs metformin
- atos diabetes
- generic actos side effects